Potential Association between Kaposi Sarcoma and Gout: An Exploratory Observational Study

Table 1

Patients’ characteristics, n = 366.

Factor	CKS cohort, n = 61	General sarcoma cohort, n = 300	value	OR
Median age, years (range)	78 (39–94)	68 years (39–99)	<0.0001 (95% CI 4.97–12.20)	—
Male sex, n (%)	46 (75.4%)	155 (51.7%)	<0.0007	2.9, 95% CI 1.53–5.36
Hypertension, n (%)	42 (68.8%)	168 (56%)	0.06	1.7, 95% CI 0.96–3.13
Diabetes mellitus, n (%)	24 (39.3%)	88 (29.3%)	0.12	1.6, 95% CI 0.88–2.76
Oral steroid use, n (%)	13 (21.3%)	70 (23.3%)	0.73	0.89, 95% CI 0.45–1.74
Gout, n (%)	11 (18%)	8 (2.6%)	<0.00001	8.0, 95% CI 3.08–20.94
Regular allopurinol use, n (%)	10 (16.4%)	10 (3.3%)	<0.0001	5.7, 95% CI 2.25–14.34

CKS, classical Kaposi sarcoma; n, number; OR, odds ratio.